Why the public should have a say in high-cost drug subsidies
By Sally Wortley and Deme Karikios
28 Jan 2015
Decisions about public subsidies for high-cost drugs are naturally quite complex. And while patients have increasingly been given a voice in the process, the views of the wider community have generally not been sought. But given the rising cost of new drugs, perhaps it’s time to widen the discussion and start a debate about equity ...